Current and Upcoming Lung Cancer Research

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.

Dr. Ramaswamy Govindan, Washington U at St. Louis, discusses patient screening, new research in targeted therapies, as well as the continued role of traditional chemotherapy in lung cancer.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The FirstLook liquid biopsy, when used as an adjunct to low-dose CT, may help to address the unmet need of low lung cancer screening utilization.
An 80% sensitivity for lung cancer was observed with the liquid biopsy, with high sensitivity observed for early-stage disease, as well.
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Related Content
A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Tislelizumab Significantly Boosts Survival in Lung Cancer Trials

Russ Conroy
April 23rd 2025
Article

A systematic review shows that well-designed randomized clinical trials are necessary to optimize treatment strategies with tislelizumab in lung cancer.

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 16th 2024
Podcast

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Ivonescimab/Chemo Prolongs PFS in 1L Advanced Squamous NSCLC

Tim Cortese
April 23rd 2025
Article

The phase 3 HARMONi-6 trial found invonescimab plus chemotherapy improved PFS vs tislelizumab plus chemotherapy in squamous NSCLC.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Cemiplimab Continues to Show Benefit Vs Chemo in PD-L1 ≥50% NSCLC

Tim Cortese
April 20th 2025
Article

A 5-year follow-up of the phase 3 EMPOWER-Lung 1 showed the greatest survival benefits in patients with NSCLC who have a PD-L1 expression of 90% or more.

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.

Mindfulness/Activity Program May Ease Anxiety Over Death from Lung Cancer

Roman Fabbricatore
April 19th 2025
Article

End-of-life demands card game and mindfulness-based cancer recovery program use may enhance the quality of life for patients with lung cancer.